Carbone Manuel Glauco, Tagliarini Claudia, Della Rocca Filippo, Flamini Walter, Pagni Giovanni, Tripodi Beniamino, Marazziti Donatella, Maremmani Icro
Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 57, 56100 Pisa, Italy.
Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Viale Luigi Borri 57, 21100 Varese, Italy.
Case Rep Psychiatry. 2021 Apr 22;2021:5567152. doi: 10.1155/2021/5567152. eCollection 2021.
Hiccups are sudden, repeated, and involuntary contractions of the diaphragm muscle (myoclonic contraction). It involves a reflex arc that, once activated, causes a strong contraction of the diaphragm immediately followed by the closure of the glottis translating into the classic "hic" sound. Hiccups can be short, persistent, and intractable depending on the duration. The most disabling hiccups often represent the epiphenomenon of a medical condition such as gastrointestinal and cardiovascular disorders; central nervous system (CNS) abnormalities; ear, nose, and throat (ENT) conditions or pneumological problems; metabolic/endocrine disorders; infections; and psychogenic disorders. Some drugs, such as aripiprazole, a second-generation antipsychotic, can induce the onset of variable hiccups. We describe herein the cases of three hospitalized patients who developed insistent hiccups after taking aripiprazole and who positively responded to low doses of gabapentin. It is probable that aripiprazole, prescribed at a low dosage (<7.5 mg/day), would act as a dopamine agonist by stimulating D and D receptors at the "hiccup center" level-located in the brain stem-thus triggering the hiccup. On the other hand, gabapentin led to a complete regression of the hiccup probably by reducing the nerve impulse transmission and modulating the diaphragmatic activity. The present case series suggests the use of low doses of gabapentin as an effective treatment for aripiprazole-induced hiccups. However, our knowledge of the neurotransmitter functioning of the hiccup reflex arc is still limited, and further research is needed to characterize the neurotransmitters involved in hiccups for potential novel therapeutic targets.
打嗝是膈肌的突然、反复且不自主的收缩(肌阵挛性收缩)。它涉及一个反射弧,一旦被激活,会导致膈肌强烈收缩,随后声门关闭,从而产生典型的“嗝”声。根据持续时间,打嗝可以是短暂的、持续的和难治的。最使人致残的打嗝往往是诸如胃肠道和心血管疾病、中枢神经系统(CNS)异常、耳鼻喉(ENT)疾病或肺部问题、代谢/内分泌紊乱、感染以及精神性疾病等病症的附带现象。一些药物,如第二代抗精神病药物阿立哌唑,可诱发不同程度的打嗝。我们在此描述了三名住院患者的病例,他们在服用阿立哌唑后出现持续性打嗝,且对低剂量加巴喷丁有积极反应。低剂量(<7.5毫克/天)的阿立哌唑可能通过刺激位于脑干的“打嗝中枢”水平的D和D受体,充当多巴胺激动剂,从而引发打嗝。另一方面,加巴喷丁可能通过减少神经冲动传递和调节膈肌活动,使打嗝完全缓解。本病例系列提示低剂量加巴喷丁可作为治疗阿立哌唑所致打嗝的有效方法。然而,我们对打嗝反射弧神经递质功能的了解仍然有限,需要进一步研究来确定参与打嗝的神经递质,以寻找潜在的新治疗靶点。